Neurotransmitter-Related Molecular Modeling Studies
This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (188 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545069504498 |
---|---|
ctrlnum |
(CKB)5690000000011949 (oapen)https://directory.doabooks.org/handle/20.500.12854/87533 (EXLCZ)995690000000011949 |
collection |
bib_alma |
record_format |
marc |
spelling |
Nowaczyk, Alicja edt Neurotransmitter-Related Molecular Modeling Studies Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (188 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life. English Research & information: general bicssc Chemistry bicssc white matter hyperintensities dysautonomia genetic polymorphisms dementia levodopa renin-angiotensin system orthostatic hypotension reserpine-induced fibromyalgia model vortioxetine ropinirole serotonin and dopamine in fibromyalgia mouse dopamine acetylcholine glutamate BDNF serotonin neurotransmitters statins neurodegenerative diseases stroke depression androgenetic alopecia 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors mixed dyslipidemia risk factors halogenated pyrazolines monoamine oxidase inhibitors kinetics reversibility molecular dynamics guanylate cyclase (GC) chronic heart failure (CHF) pulmonary arterial hypertension (PAH) tiagabine cardiac voltage-gated ion channels molecular modeling ECG study SGLT2i sodium-glucose cotransporter 2 inhibitors neuroprotection atheroprotection mTOR type 2 diabetes mellitus cognitive impairment inflammation oxidative stress antibiotics neurotoxicity adverse drug reaction neurotransmission 5-HT receptors gastrointestinal tract 3-0365-4277-9 3-0365-4278-7 Grześk, Grzegorz edt Nowaczyk, Alicja oth Grześk, Grzegorz oth |
language |
English |
format |
eBook |
author2 |
Grześk, Grzegorz Nowaczyk, Alicja Grześk, Grzegorz |
author_facet |
Grześk, Grzegorz Nowaczyk, Alicja Grześk, Grzegorz |
author2_variant |
a n an g g gg |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Neurotransmitter-Related Molecular Modeling Studies |
spellingShingle |
Neurotransmitter-Related Molecular Modeling Studies |
title_full |
Neurotransmitter-Related Molecular Modeling Studies |
title_fullStr |
Neurotransmitter-Related Molecular Modeling Studies |
title_full_unstemmed |
Neurotransmitter-Related Molecular Modeling Studies |
title_auth |
Neurotransmitter-Related Molecular Modeling Studies |
title_new |
Neurotransmitter-Related Molecular Modeling Studies |
title_sort |
neurotransmitter-related molecular modeling studies |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (188 p.) |
isbn |
3-0365-4277-9 3-0365-4278-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT nowaczykalicja neurotransmitterrelatedmolecularmodelingstudies AT grzeskgrzegorz neurotransmitterrelatedmolecularmodelingstudies |
status_str |
n |
ids_txt_mv |
(CKB)5690000000011949 (oapen)https://directory.doabooks.org/handle/20.500.12854/87533 (EXLCZ)995690000000011949 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Neurotransmitter-Related Molecular Modeling Studies |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796651448320131072 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04362nam-a2200961z--4500</leader><controlfield tag="001">993545069504498</controlfield><controlfield tag="005">20231214133523.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202207s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5690000000011949</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/87533</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995690000000011949</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nowaczyk, Alicja</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurotransmitter-Related Molecular Modeling Studies</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (188 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemistry</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">white matter hyperintensities</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dysautonomia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic polymorphisms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dementia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">levodopa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renin-angiotensin system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">orthostatic hypotension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reserpine-induced fibromyalgia model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vortioxetine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ropinirole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serotonin and dopamine in fibromyalgia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mouse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dopamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetylcholine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutamate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BDNF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serotonin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotransmitters</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">statins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurodegenerative diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stroke</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">depression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgenetic alopecia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mixed dyslipidemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">halogenated pyrazolines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">monoamine oxidase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reversibility</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular dynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">guanylate cyclase (GC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic heart failure (CHF)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary arterial hypertension (PAH)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tiagabine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiac voltage-gated ion channels</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular modeling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ECG study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SGLT2i</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sodium-glucose cotransporter 2 inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuroprotection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atheroprotection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">type 2 diabetes mellitus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cognitive impairment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotransmission</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-HT receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastrointestinal tract</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4277-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4278-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grześk, Grzegorz</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nowaczyk, Alicja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grześk, Grzegorz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:34 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-14 08:50:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337823410004498&Force_direct=true</subfield><subfield code="Z">5337823410004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337823410004498</subfield></datafield></record></collection> |